People's Justice
The Wire · All news

GLP-1 Vision Loss (Ozempic / Wegovy NAION)

Harvard study in JAMA Ophthalmology links semaglutide to NAION

Published Updated

By People's Justice

What happened

A Harvard Medical School team publishes a study in JAMA Ophthalmology reporting that patients prescribed semaglutide had a substantially higher risk of NAION — a hazard ratio of 4.28 among people with type 2 diabetes and 7.64 among overweight or obese patients. The authors note the study is observational and call for further research.

Event date:

Source: pubmed.ncbi.nlm.nih.gov

GLP-1 Vision Loss (Ozempic / Wegovy NAION) case guideCheck eligibility

Related news

  1. GLP-1 Vision Loss (Ozempic / Wegovy NAION)

    Federal Lawsuits Over GLP-1 Drugs and Rare Vision Loss Top 200

    News outlets reported that over 200 federal lawsuits have been filed alleging GLP-1 drugs such as Ozempic, Wegovy, and Mounjaro caused NAION, a rare and often permanent form of vision loss. Manufacturers reportedly dispute the claims, and plaintiffs allege they were not adequately warned of the risk.

    Source: yahoo.com

  2. GLP-1 Vision Loss (Ozempic / Wegovy NAION)

    Media Reports Detail Hundreds of GLP-1 Vision Loss Lawsuits; New Research Examines Eye Risks

    The New York Post reported that a man's claim of sudden, permanent blindness after using Ozempic is one of hundreds of lawsuits filed against GLP-1 drug makers alleging inadequate warning of vision loss risk. Separately, a Medical Economics roundup noted reporting that Wegovy may carry a higher risk of 'eye stroke' than other GLP-1 drugs, and a systematic review in the Canadian Journal of Ophthalmology examined a possible link between GLP-1 receptor agonist use and age-related macular degeneration.

    Source: news.google.com

  3. GLP-1 Vision Loss (Ozempic / Wegovy NAION)

    Hundreds of Lawsuits Filed Alleging GLP-1 Drugs Caused Vision Loss

    News reports from the New York Post and other outlets describe hundreds of lawsuits against GLP-1 drug makers, with plaintiffs alleging the drugs were not adequately labeled to warn of potential vision loss. A separate report notes Wegovy may carry a higher risk of 'eye stroke' than other GLP-1 drugs, and a new systematic review examined possible links between GLP-1 receptor agonist use and age-related macular degeneration.

    Source: news.google.com